New Haven, CT – According to filings with the U.S. Securities and Exchange Commission, Osmol Therapeutics is raising $7,500,000.00 in new funding. Sources indicate as part of senior management President and Chief Executive Officer, Robert Berman played a key role in securing the recent investment and it will aid in aggressively expanding the company, as well as broaden and accelerate product development.

About Osmol Therapeutics
Osmol Therapeutics, Inc. is a development-stage biopharma company based in New Haven, Connecticut advancing a novel treatment to prevent chemotherapy-induced peripheral neuropathy and other diseases driven by calcium dysregulation. Chemotherapy-induced peripheral neuropathy (CIPN) affects hundreds of thousands of cancer patients every year, and can compromise optimum chemotherapy dosing. There are no effective treatments for CIPN, a condition which can diminish quality of life and lead to lifelong disability. Taxane-based chemotherapy agents used to treat breast cancer patients are particularly problematic where CIPN occurrence is as high as 80%. Osmol is Developing a Treatment to Prevent CIPN Before it Starts. Data from preclinical studies conducted by Osmol show that pretreatment with OSM-0205 prevents neuronal damage from taxanes in mice by preventing the off-target intracellular calcium surge caused by these chemotherapy agents. It is hypothesized that OSM-0205 in patients will protect neurons from damage leading to a reduction of CIPN. This prevention of CIPN will allow more optimal chemotherapy dosing.

To learn more about Osmol Therapeutics, visit http://www.osmoltherapeutics.com/

Contact:
Robert Berman, President and Chief Executive Officer
617-719-9406
https://www.linkedin.com/in/rob-berman-b280996/

SOURCE: http://www.intelligence360.io
Copyright (c) 2021 SI360 Inc. All rights reserved